肿瘤自身抗体NY-ESO-1和PRDX6联合热休克蛋白70检测对肺癌的诊断价值

Value of joint detection of NY-ESO-1,peroxiredoxin 6 and heat shock protein 70 autoantibodies to the diagnosis of lung cancer

目的探讨肿瘤自身抗体NY-ESO-1、peroxiredoxin 6(PRDX6)和热休克蛋白70(heat shock protein 70,HSP70)联合检测在肺癌诊断中的应用价值。方法采用ELISA法检测92例肺癌患者(肺癌组)和80例体检健康者(对照组)血清NY-ESO-1、PRDX6和HSP70表达水平,应用ROC曲线分析3项自身抗体联合诊断肺癌的效能。结果肺癌组血清NY-ESO-1[0.206(0.132,0.361)]、PRDX6(0.140±0.078)和HSP70(0.105±0.087)自身抗体水平明显高于对照组[0.095(0.055,0.145)、0.094±0.038、0.059±0.035],差异有统计学意义(P<0.01);血清NY-ESO-1自身抗体水平在年龄>60岁肺癌患者[0.325(0.161,0.683)]高于年龄≤60岁者[0.163(0.118,0.241)],有淋巴结转移者[0.229(0.132,0.431)]高于无淋巴结转移者[0.160(0.102,0.207)](P<0.05),在性别、组织病理类型和TNM分期上差异无统计学意义(P>0.05);血清PRDX6和HSP70自身抗体水平在年龄、性别、有无淋巴结转移、组织病理类型和TNM分期上差异均无统计学意义(P>0.05);血清NY-ESO-1、PRDX6和HSP70自身抗体诊断肺癌的敏感度分别为54.3%、30.4%、26.1%,特异度分别为92.5%、92.5%、92.5%;3种自身抗体联合检测诊断肺癌的敏感度为63.0%,特异度为91.2%,诊断敏感度高于单项指标检测,特异度略下降但差异无统计学意义(P<0.05)。结论血清NY-ESO-1、PRDX6和HSP70自身抗体联合检测诊断肺癌具有较高的敏感性,有可能用于肺癌的筛查和诊断。

Objective To explore the value of joint detection of serum NY-ESO-1, peroxiredoxin 6 （PRDX6） and heat shock protein 70 （HSP70） autoantibodies to the diagnosis of lung cancer. Methods The serum levels of NY-ESO-1, PRDX6 and HSP70 autoantibodies were measured in 92 patients with lung cancer （cancer group） and 80 health volunteers （control group） by ELISA method. The diagnostic value of joint detection was evaluated by using ROC curve. Results The serum levels of NY-ESO-1, PRDX6 and HSP70 autoantibodies were significantly higher in cancer group （0. 206 （0. 132, 0. 361）, 0. 140±0. 078, 0. 105±0. 087） than those in control group （0. 095（0. 055, 0. 145）, 0. 094±0. 038, 0. 059±0. 035） （P〈0.01）. The NY ESO-1 level was higher in 〉60-year-old patients （0. 325（0. 161, 0. 683）） than that in 〉60-year-old patients （0. 163 （0. 118, 0. 241））, and higher in those with lymph node metastasis （0. 229 （0. 132, 0.431）） than that in those with no lymph node metastasis （0. 160（0. 102, 0. 207）） （P〈0.05）, and there were no significant differences in gender, pathological classification and TNM stage （P〉0.05） in cancer group. The NY-ESO 1 and HSPT0 autoantibodies levels showed no significant differences in the age, gender, lymph node metastasis, pathological classification and TNM stage （P〉0.05）. The sensitivities of NY ESO-1, PRDX6 and HSP70 autoantibodies for lung cancer were 54.3%, 30.4% and 26.1%, respectively, and the specificities were 92.6%, 92.5% and 92.5%. The sensitivity of joint detection of the three autoantibodies was 63.0%, significantly higher than that of detection of each single index, and the specificity was slightly lower （91.2%）, showing no significant difference （P〈0.05）. Conclusion Joint detection of NY-ESO 1, PRDX6 and HSP70 autoantibodies has a high sensitivity for lung cancer, which would be a potential biomarker for screening and diagnosis of lung cancer.